A
Abdel-Moneim M. Osman
Researcher at Cairo University
Publications - 57
Citations - 1377
Abdel-Moneim M. Osman is an academic researcher from Cairo University. The author has contributed to research in topics: Cardiotoxicity & Doxorubicin. The author has an hindex of 21, co-authored 55 publications receiving 1153 citations. Previous affiliations of Abdel-Moneim M. Osman include Helwan University & King Abdulaziz University.
Papers
More filters
Journal ArticleDOI
Dibutyl phthalate induces oxidative stress and impairs spermatogenesis in adult rat
Hamdy A.A. Aly,Hamdy A.A. Aly,Memy H. Hassan,Memy H. Hassan,Hesham A. El-Beshbishy,Hesham A. El-Beshbishy,Abdulrahman M. Alahdal,Abdel-Moneim M. Osman +7 more
TL;DR: Results indicated that oxidative stress and subsequent decrease in testosterone secretion were the potential underlying mechanism of DBP-induced testicular toxicity.
Journal ArticleDOI
Diurnal distribution of airborne bacteria and fungi in the atmosphere of Helwan area, Egypt.
TL;DR: Geographical location, human activity, growth cycle of organisms and meteorological factors were the main criteria controlling the temporal variations of the air microorganisms in the Wadi Hof area.
Journal ArticleDOI
Increased plasma endothelin-1 and cardiac nitric oxide during doxorubicin-induced cardiomyopathy.
TL;DR: The results show that doxorubicin caused a statistically significant increase of 85%, 76% and 97% in plasma endothelin-1 at a cumulative dose levels of 10, 15 and 20 mg/kg, respectively, however, the level of plasma nitric oxide remained unchanged.
Journal ArticleDOI
Aged garlic extract protects against doxorubicin-induced cardiotoxicity in rats.
Huda M. Alkreathy,Zoheir A. Damanhouri,Nessar Ahmed,Mark Slevin,Soad S. Ali,Abdel-Moneim M. Osman +5 more
TL;DR: The results suggest that aged garlic extract is potentially protective against doxorubicin-induced cardiotoxicity, and total antioxidant activity was increased after aged garlic Extract administration.
Journal ArticleDOI
Major obstacles to doxorubicin therapy: Cardiotoxicity and drug resistance.
TL;DR: The major obstacles to doxorubicin therapy, doxorbicin-induced cardiotoxicity as well as the mechanisms of cancer drug resistance and in following the treatment failures are described.